Euformatics partners with Appolon Bioteck to expand in the French market
Press Release Espoo, September 6th, 2023
Euformatics, a Finnish bioinformatics company that develops world-leading genomic data analysis tools, announced that it has signed a new channel partnership with Appolon Bioteck. As part of the collaboration, Appolon Bioteck and Euformatics plan to locally market NGS data analysis tools to help French medical geneticists and molecular pathologists diagnose patients effectively and based on high-quality data.
The collaboration covers the full suite of Euformatics bioinformatics tools for NGS data analysis. The secondary analysis module takes care of the computational heavy lifting of read alignment and variant calling from the raw sequence data. The variants are then automatically transferred to the tertiary analysis module, which automates the process of annotation, classification, interpretation and reporting of clinically relevant variants. This clinical workflow is controlled by a comprehensive quality control module that calculates up to 60 quality metrics from the FASTQ, BAM and VCF files that the bioinformatics process produces. QC service includes a service for NGS test validation that the laboratory can use when introducing new tests to their portfolio and needing to validate the performance of the pipeline.
Laurent Slusarek, General Manager of Appolon Bioteck, says, “Our team understands the characteristics and requirements of the French molecular diagnostics labs very well. Our objective is to deliver them the highest quality instruments, consumables and software to enable high-quality care. Euformatics traction both in the French market and more broadly in Europe recently coupled with the workflow automation enabled by the Genomics Hub tools convinced us that these products fit well to the French market.”
Euformatics’ CEO, Tommi Kaasalainen continues, “We are very happy to sign Appolon as our local partner in France. Their understanding of the diagnostics business is top notch, and I am confident that they will get up to speed fast as we are already working on multiple cases together and planning joint go-to-market activities. Our current and future customers in the French market will greatly benefit from Appolon’s expertise.”
This contract marks the 20th channel partnership agreement Euformatics has signed during the past few years, covering the Americas, Europe, the Middle East and Asia. Finding the best local partners continues to be one of the strategic priorities for the company.
About Appolon Bioteck:
APPOLON BIOTECK is a French company with expertise in molecular biology applied to medical diagnostics since 2011. As such, we provide a very comprehensive range of solutions for molecular biology laboratories in France and around the world. Our product range is constantly evolving and adapting to keep pace with advances in medical biology research and therapeutic innovations while incorporating the latest technological solutions.
To learn more, visit https://appolonbioteck.com/
Euformatics is a Finnish software company that specialises in high-standard bioinformatics tools for genomic data interpretation. Since 2010, Euformatics has been helping medical doctors and molecular genetics laboratories provide better precision medicine for cancer and common or rare disease diagnostics. At present, our core solution is the Genomics Hub which includes a variant interpretation tool; for clinical analysis and reporting of patient NGS data and a quality control tool; for NGS data quality management.
To learn more, visit www.euformatics.com